Novel mutations in CYP4V2 in Bietti corneoretinal crystalline dystrophy: Next-generation sequencing technology and genotype-phenotype correlations

Xiao Hong Meng, Yan He, Tong Tao Zhao, Shi Ying Li, Yong Liu, Zheng Qin Yin

Southwest Hospital/Southwest Eye Hospital, Army Medical University, Chongqing, China; Key Lab of Visual Damage and Regeneration & Restoration of Chongqing, China

Purpose: To identify any novel mutations in CYP4V2 in 85 Chinese families with Bietti corneoretinal crystalline dystrophy (BCD) by using next-generation sequencing, and to summarize the mutation spectrum in this population, along with any genotype-phenotype correlations.

Methods: A total of 90 patients with BCD from 85 unrelated Chinese families were recruited. All probands were analyzed by using gene chip-based next-generation sequencing, to capture and sequence all the exons of 57 known hereditary retinal degeneration-associated genes. The candidate variants were validated with PCR and Sanger sequencing.

Results: Twenty-eight mutations were detected in all patients, including thirteen novel mutations (five missense, six deletions, one splicing and one frame-shift mutations) and 15 previously reported mutations. Mutations in 64 patients were inherited from their parents, while three patients had de novo mutations. c.802–8_810del17insGC was the most common mutation, accounting for 78% of the mutations. Although 16 patients were homozygous at this site, the clinical features of all 16 patients were highly heterogeneous.

Conclusions: These results expand the spectrum of mutations in CYP4V2, and suggest that mutations in CYP4V2 may be common in the Chinese population. The phenotype of patients with the homozygous mutation (hom.c.802–8_810del17insGC) is highly heterogeneous.

Bietti corneoretinal crystalline dystrophy (BCD, OMIM 210370) is an autosomal recessive retinal dystrophy, characterized by numerous tiny glistening yellow-white crystals scattered at the posterior pole of the retina, progressive atrophy of the RPE, and choroidal sclerosis. The majority of the cases also present similar crystals at the corneoscleral limbus, and within the vitreous cavity. The disease usually occurs in the second or third decade of life, and progresses to legal blindness by the fifth or sixth decade [1]. CYP4V2 (Gene ID 285440, OMIM 210370) is currently the only identified gene associated with this disease [2,3]. BCD is relatively common in Chinese and Japanese populations [4-25], who harbor the c.802–8_810del17insGC in exon 7, c.992A>C in exon 8, and c.1091-2A>G in exon 9 mutations. These most common mutations account for 83.3% of the mutant alleles.

In a previous report, we described the spectrum of mutations in CYP4V2 in 92 Chinese patients with BCD, with Sanger sequencing [18]. Compared to Sanger sequencing, next-generation sequencing (NGS) targets the genes known to underlie BCD, and thus, has been used to encompass clinical and genetic heterogeneity of this disease group. Patients with BCD were commonly reported in an East Asian population with an estimated gene frequency of 0.005 in China [26]. The incidence of BCD also appears in a large proportion of Chinese patients with retinitis pigmentosa. To understand the spectrum of mutations in CYP4V2 within the Chinese population, further genetic counseling is essential for the diagnosis and treatment of the disease. The present study assessed the distribution and prevalence of mutations and genes involved in BCD among the Chinese population, using a comprehensive analysis of BCD through the application of an NGS panel comprising 57 genes optimized from a previous report [27].

In this study, we detected mutations in the CYP4V2 gene in 85 BCD probands from southwestern China, summarized the mutation spectrum, and analyzed the genotype-phenotype correlations.

METHODS

Recruitment of subjects: Ninety patients from 85 Chinese families with BCD were recruited from the Southwest Eye Hospital and Southwest Hospital, Chongqing, China. There were no systemic diseases such as hypertension, examinations. Family members of the probands were also
invited for clinical examination and genetic assessment. The research protocol was approved by the Ethics Review Board of the Southwest Hospital (Chongqing, China), and the study was performed in accordance with the Declaration of Helsinki and adhered to the ARVO statement on human subjects. Written informed consent was obtained from all participants. All patients underwent complete eye examinations, including best-corrected visual acuity (BCVA) testing with the fractional VA chart, slit-lamp biomicroscopy, funduscopy, fundus photodocumentation, fundus autofluorescence (AF), fundus fluorescein angiography (FFA), spectral domain optical coherence tomography (SD-OCT), and a full-field electroretinogram (FERG).

Targeted region capture and next-generation sequencing: For exome sequencing, we fragmented 1–3 μg of genomic DNA, extracted from each sample, to an average size of 180 bp with a Bioruptor sonicator (Diagenode, Liege, NJ). Paired-end sequencing libraries then were prepared using the DNA Sample Prep Reagent Set 1 (NEBNext, San Diego, CA). Library preparation included end repair, adaptor ligation, and PCR enrichment, and was performed as recommended by Illumina protocols.

Next, 57 genes associated with ophthalmologically diseases (Appendix 1) were selected with a gene capture strategy, using the GenCap custom enrichment kit (MyGenostics Inc., Beijing, China), following the manufacturer’s protocol. The biotinylated capture probes (80–120-mer), were designed to tile all of the exons with non-repeated regions. Briefly, the 1 μg DNA library was mixed with Buffer BL and the GenCap gene panel probe (MyGenostics), and heated at 95 °C for 7 min and 65 °C for 2 min on a PCR machine. Then, 23 μl of the 65 °C prewarmed Buffer HY (MyGenostics) was added to the mix, and the mixture was held at 65 °C with PCR lid heat on for 22 h for hybridization. Then, 50 μl MyOne beads (Life Technology, Carlsbad, CA) was washed in 500 μl 1X binding buffer three times, and resuspended in 80 μl 1X binding buffer. About 64 μl 2X binding buffer was added to the hybrid mix, and transferred to the tube with the 80 μl MyOne beads. The mix was rotated for 1 h on a rotator. The beads were then washed with WB1 buffer at room temperature for 15 min once and WB3 buffer at 65 °C for 15 min three times. The bound DNA was then eluted with buffer elute. The eluted DNA was finally amplified for 15 cycles using the following program: 98 °C for 30 s (1 cycle); 98 °C for 25 s, 65 °C for 30 s, 72 °C for 30 s (15 cycles); and 72 °C for 5 min (1 cycle). The PCR product was purified using SPRI beads (Beckman Coulter, Brea, CA) according to the manufacturer’s protocol. The enrichment libraries were sequenced on the Illumina HiSeq X ten sequencer for a 150 bp paired read.

Variant identification and validation: After sequencing, the raw data were saved in the FASTQ format. Then, the bioinformatics analysis was performed: First, Illumina sequencing adapters and low-quality reads (<80 bp) were filtered by cutadapt. After quality control, the clean reads were mapped to the UCSC hg19 human reference genome using BWA [27] (http://bio-bwa.sourceforge.net/). Duplicated reads were removed using picard tools, and mapping reads were used to detect variations. Second, single nucleotide polymorphism (SNPs) and insertion and deletion variants were detected with GATK HaplotypeCaller. Then, using GATK VariantFiltration to filter the variants, the filtered standard as follows: a) variants with mapping qualities <30; b) the total mapping quality zero reads <4; c) approximate read depth <5; d) QUAL<50.0; and e) phred-scaled p value using Fisher’s exact test to detect strand bias >10.0. After the two steps, the data were transformed into the VCF format. Variants were further annotated with ANNOVAR [28], and associated with multiple databases, such as 1000 genome, ESP6500, dbSNP, EXAC, and HGMD, and predicted with Sorting Intolerant From Tolerant (SIFT), PolyPhen-2, MutationTaster, and GERP++. Genomic DNA from all available family members were obtained for Sanger sequencing. The PCR samples were visualized on agarose gels, purified, and sequenced on an ABI PRISM 3730 genetic analyzer (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA), using the terminator cycle sequencing method. Sites of variation were identified through a comparison of DNA sequences with the corresponding GenBank reference sequences.

Identification of mutations in CYP4V2: Approximately 221,340 kb of the exons and adjacent intronic regions of 57 genes associated with ophthalmological diseases were captured and sequenced from every proband. The mean coverage of the 57 genes associated with retinitis pigmentosa (RP) was about 99.6%, and the median depth was 509X. A mean of 94.7% of the base pairs with N20X coverage was successfully for each gene, indicating a high capability for identifying variants.

The CYP4V2 sequence was compared with the NCBI reference sequence for the CYP4V2 transcript variant (GenBank ID; NM_207352.4) for allowing direct comparison with known mutations in CYP4V2 in the Human Gene Mutation Database (HGMD). To confirm the variants in CYP4V2, and to assess the inheritance pattern of Bietti crystalline corneoretinal dystrophy in the probands, Sanger sequencing was used to analyze the variants in the probands and their family members.
RESULTS

Clinical findings: The cohort included five probands whose parents were consanguineous. Of the 85 probands, 46 were male, and 39 were female. The most common initial complaint was poor vision or night blindness starting between the age of 10 and 40 years, followed by vision reduction; three patients complained of visual distortion. Slit-lamp examination revealed crystalline deposits at the corneoscleral limbus in 80 patients. In most patients, fundus examination showed the presence of numerous tiny, glistening yellow-white crystals scattered at the macular area and posterior pole of the retina, atrophy of the RPE, and choroidal sclerosis. VA varied markedly from light perception to 1.0. Only one proband showed a normal visual field, and two patients had normal FERG recordings, while most patients exhibited a reduced FERG.

Concomitant ocular diseases included macular edema in three patients, cataract in 25 patients, choroidal neovascularization (CNV) in one patient, macular hole in two patients, and high myopia in 16 patients. The macular membrane was noted in five patients. Three patients did not show any clinical symptoms in pedigree screening, and none of the patients had hypertension, high blood lipids, or diabetes.

Mutation analysis: According to the complete sequence analysis of the coding and adjacent intronic regions of CYP4V2, homozygous, compound heterozygous, and heterozygous CYP4V2 was detected in 29 families, 50 families, and one family, respectively. A total of 28 mutations were identified, of which seven were novel (Table 1). The mutations c.802–8_810del17insGC, c.1091–2A>G, and c.992A>G were detected in 47, 22, and 25 unrelated families, respectively. The proportion of these three common mutations was 81.25%. The most common mutation, c.802–8_810del17insGC, was identified homozygous in 16 unrelated families. The homozygous mutation c.992A>C occurred in eight unrelated families, while the homozygous mutation c.1091–2A>G was found in five unrelated families. The compound heterozygous mutations c.802–8_810del17insGC and c.992A>C were identified in seven unrelated families, while c.802–8_810del17insGC and c.1091–2A>G were identified in 15 unrelated families. No statistically significant differences were detected in the age of onset and course of the illness among these types of mutations (Table 2).

Clinical features of patients with a Hom. 802–8_810del17insGC mutation: Sixteen probands with BCD (six men and ten women, average age 38 years) harbored a Hom. c.802–8_810del17insGC mutation. The age of onset of vision reduction and night blindness ranged from 10 to 46 years, while the age when patients first visited a doctor ranged from 20 to 68 years (average age, 27.5 years; Appendix 2). We analyzed the clinical features of seven patients with BCD aged between 20 and 30 years [patient 1 (P1), P3, P4, P6, P7, P13, and P15] with an age of onset of 15 to 30 years old. The visual field defects among the seven patients indicated several differences (Appendix 2).

The fundus of the P1, P3, P4, P6, P13, and P15 patients showed signs of severe RPE atrophy, choroidal sclerosis, and a rare distribution of crystallization (Figure 1A, P4). Fundus fluorescein angiography of patient P4 showed atrophy of the RPE and choroidal capillaries with mottled hypofluorescence (Figure 1B, P4). VA was decreased markedly with an irregular visual field defect (Figure 1C, P4). Loss of the connective and ellipsoid band of the outer retina, thinning of the RPE, and choroid thickening were shown on the SD-OCT. In addition, severely reduced amplitudes were observed in rod and cone ERGs (Figure 2, P4). Patient P6 exhibited a large amount of crystalline particle deposition in the fundus, slight RPE atrophy (Figure 1F, P6), and slightly reduced amplitudes in rod and cone ERGs (Figure 2, P6). Patient P7 did not show any symptoms of night blindness, and received intravitreal injections of ranibizumab, owing to CNV in the left eye. Only a slight crystalline formation was observed within the macular region of patient P7 (Figure 1K, P7), although spiced-salt-shaped and map-shaped hypoautofluorescent regions were observed (Figure 1L, P7). VA of the two eyes had decreased slightly (Figure 1H, M), while SD-OCT showed that the structure of the outer retina was complete albeit with choroidal thinning (Figure 1J, N, O); however, the ERGs were normal (Figure 2, P7). Patient P9 first presented at 50 years of age, although the onset of symptoms had occurred 10 years earlier, and had been associated with a diffused decrease in VA. Fundus examination showed RPE atrophy, a small amount of crystallization, and slight choroid sclerosis that was limited to the posterior pole. Diffuse and hypofluorescence were shown in the AF; however, the FERG was normal. Consequently, a total of 28 mutations were identified, and seven mutations were novel (Table 1). The mutations c.802–8_810del17insGC, c.1091–2A>G, and c.992A>G were detected in 47, 22, and 25 unrelated families, respectively. The proportion of these three common mutations was 81.25%.

DISCUSSION

We applied targeted NGS technology to detect pathogenic mutations in 85 probands with BCD. Seven novel mutations were found, which expanded the spectrum of mutations in CYP4V2. To date, the study group has revealed the spectrum
of mutations in CYP4V2 of patients with BCD from the Chinese population with the largest sample (including the 92 cases in the previous report) [16]. The most common mutation in CYP4V2 in the Chinese BCD population is c.802–8_810del17insGC, compared to non-Asian patients with BCD, which indicates potential relationships with coancestors. Thus, mutations in CYP4V2 are known to be related to ethnic origins.

In a previous study, Sanger sequencing was performed for 92 cases, while 85 cases were subjected to NGS in the present study, indicating that patients carrying a heterozygous CYP4V2 mutation is a common characteristic of the Chinese population. Only five children from consanguineous marriages and 16 probands from non-consanguineous marriages carried the homozygous c.802–8_810del17insGC mutation. Therefore, we speculated that this deletion/insertion mutation is caused by coancestry by prolonged harboring, and is the genetic basis of the high incidence of BCD in the Chinese population. In some cases, an autosomal recessive inheritance mode was ignored, due to the lack of verification of the parents and the sporadic nature of the BCD patient diagnosis. Therefore, in consideration of the common heterozygous carriers of mutations in CYP4V2 in the Chinese population, it is necessary to undergo genetic screening and counseling before a birth plan.

The CYP4V2 gene contains 11 exons spanning 19 kb. The coding sequence begins in exon 1, and continues through exon 11 [29]. CYP4V2 is homologous to other members of

| Exon   | Nucleotide change                             | Amino acid change | report       |
|--------|----------------------------------------------|-------------------|--------------|
| Exon1  | c.65T>A                                       | p.L22H            | reported [23]|
| Intron1| c.215-2A>G                                    | splicing          | Reported [15]|
| Exon2  | c.219T>A                                     | p.F73L            | Reported [42]|
| Intron1| c.215-1G>T                                    | splicing          | Reported [15]|
| Exon2  | c.283G>A                                     | p.G95R            | Reported [7]  |
| Exon4  | c.492delT                                     | p.D164EfsX3       | novel        |
| Exon7  | c.802-6_810delATACAGGTACGCT                   | p.268-270del      | novel        |
| Intron3| c.413+2T>G                                    | splicing          | Reported [18]|
| Exon4  | c.414_450del                                  | p.S138Rfs*1       | novel        |
| Exon7  | c.808-8_810del17insGC                         | p.V268fs*7        | Reported [8] |
| Exon7  | c.810del T                                   | p.A270fs          | Reported [26]|
| Exon7  | c.804-6_810del                               | p.V268_270del     | novel        |
| Exon7  | c.796-810del                                 | p.268_270del      | novel        |
| Exon7  | c.802-8-807delCATAACGTCGC                     | deleting          | novel        |
| Exon7  | c.958C>T                                     | p.R320X           | Reported [15]|
| Exon8  | c.988G>A                                     | p.G330 R          | novel        |
| Exon8  | c.992A>C                                     | p.H331P           | Reported [3] |
| Exon8  | c.1020G>A                                    | p.W340X           | Reported [8] |
| Exon8  | c.1057dupA                                   | p.V355S fs*4      | novel        |
| Intron8| c.1091-2A>G                                  | splicing          | Reported [8] |
| Exon9  | c.1199G>A                                    | p.R400H           | Reported [7] |
| Exon9  | c.1168C>T                                    | p.R390C           | Reported [16]|
| Exon9  | c.1187C>G                                    | p.P396R           | novel        |
| Exon10 | c.1247G>T                                    | p.G416V           | novel        |
| Exon10 | c.1354C>T                                    | p.R452C           | novel        |
| Exon10 | c.1384G>C                                    | p.A462P           | novel        |
| Exon10 | c.1396A>G                                    | p.N466 D          | Reported [39]|
| Intron10| c.1406-1G>A                                  | splicing          | novel        |
Table 2. Clinical features of common CYP4V2 mutation types in 85 probands with Bietti’s Crystalline Dystrophy.

| Types                                  | Number of patients | Visual acuity (mean) | Age at consultation (years) | Age at onset (years) | Course of the disease (years) |
|----------------------------------------|--------------------|----------------------|-----------------------------|---------------------|------------------------------|
| Hom.c.802-8_810del17insGC              | 16                 | 0.42±0.54            | 38.1±12.8                   | 27.0±10.0           | 10.75±6.07                   |
| c.802-8_810del17insGC & c.992A>C       | 7                  | 0.27±0.23            | 42.2±7.62                   | 32.6±9.45           | 9.60±3.26                    |
| c.802-8_810del17insGC & c.1091-2A>G    | 15                 | 0.32±0.24            | 40.53±10.99                 | 30.47±11.73         | 10.0±8.95                    |
| Hom. c.992A>G                          | 8                  | 0.25±0.25            | 45.0±7.75                   | 32.12±6.10          | 12.88±5.99                   |
| Hom. c.1091-2A>G                       | 5                  | 0.22±0.12            | 46.6±6.43                   | 29.6±10.52          | 17.0±14.07                   |
CYP450 family 4. Cytochrome P450s are heme-thiolate proteins involved in the oxidative degradation of various compounds. Sequence conservation is relatively low within the family (there are only three absolutely conserved residues), but their general topography and structural fold are highly conserved. The conserved core is composed of a coil termed the “meander,” a four-helix bundle, helices J and K, and two sets of beta-sheets. These constitute the heme-binding loop (with an absolutely conserved cysteine that serves as the 5th ligand for the heme iron), the proton-transfer groove, and the absolutely conserved EXXR motif in helix K \[^{30-35}\]. In this study, we found eight novel mutations, including two...
missense mutations, one nonsense mutation, three deletion mutations, and one splicing mutation. These mutation sites are located within the CYP4V2 protein domain, and these sites are relatively conserved. The pathogenicity of the nonsense mutations was determined. Deletion mutations c.802-6_810delATAACAGGTCACTGC, c.414_450del, c.492delT, c.796_810del, and c.802-8_807delATAACAGGTCACTGC lead to misalignment and rearrangement of the encoded amino acids, resulting in protein truncation and functional inactivation. For the mutation c.1406-1G>A, which has an impact on the protein domain.

Furthermore, a causal link between the mutation in CYP4V2 and the mechanism(s) causing the BCD phenotype has not been clarified [36-38]. Only a limited number of cases have been reported concerning the relationship between the CYP4V2 genotype and the BCD clinical phenotype. Lai et al. [10] summarized nine types of mutations in CYP4V2 in 18 Chinese families, and analyzed the relevant phenotypes. The results showed patients with splice-site mutations (homozygous c.802-8_810del17insGC or compound heterozygous c.802-8_810del17insGC and IVS8-2A>G) had a lower electrooculogram Arden index, and were likely to exhibit a non-recordable scotopic FERG, as well as a non-recordable 30-Hz flicker ERG. However, the influence of the age of onset and the course of the disease factors related to changes in retinal function were not reported. Halford et al. [39] analyzed the genotype and phenotype for 20 patients with BCD from 17 families, and found high variances. Gekka et al. [4] compared clinical features of two cases with a mutation in CYP4V2, and found that the patient with the homozygous deletion/insertion mutation (c.802-8_810del17insGC) showed decreased VA, constriction of the visual fields, and severely reduced amplitudes in rod and cone ERGs. Conversely, the other patient with a compound heterozygote mutation, although 6 years older, presented mild clinical manifestations, i.e., satisfactory VA and substantial amplitudes on rod and cone ERGs. Rossi et al. [40] described the clinical and genetic features of 15 Italian patients with BCD, and highlighted the lack of a clear genotype-phenotype correlation underlying the less severity of clinical manifestations that might be linked to relatively mild mutations. In addition, the study described a patient with BCD carrying the mutation in CYP4V2 and classical retinal lesions, with a normal ERG; however, a multifocal ERG showed that the central P1 wave form was completely extinguished [41]. Yin et al. [42] appraised the genotypes and phenotypes of 17 patients with BCD from 14 families, and found that the phenotype might be variable between different families, although the genotypes were identical.

This is the first study examining the differences in the phenotype among 16 probands with homozygous deletion/insertion mutation, c.802–8_810del17insGC. We found that the same type of mutation resulted in different phenotypes within the group; in particular, the phenotypic analysis in patients within the same age group revealed a high variation between the phenotype and genotype. The severity of the phenotype seems to be related to the course of the disease; the earlier the onset, the longer the duration with a severe phenotype.

**Conclusion:** We identified seven novel mutations in CYP4V2 in a population of 85 probands with BCD, thus expanding the spectrum of mutations in CYP4V2. The mutations in CYP4V2 might be widespread in the Chinese population. However, a distinct genotype-phenotype correlation among patients with homozygous deletion/insertion mutations was not observed, suggesting that heterogeneity in genotype and phenotype might underlie BCD. Thus, further studies investigating the possible mechanism(s) underlying these diverse mutations are essential.

**APPENDIX 1. FIFTY-SEVEN RP-RELATED GENES BY TARGETED REGION CAPTURE AND NEXT-GENERATION SEQUENCING.**

To access the data, click or select the words “Appendix 1.”

**APPENDIX 2. CLINICAL FEATURES OF PATIENTS WITH A HOM.C.802–8_810DEL17INS GC MUTATION.**

To access the data, click or select the words “Appendix 2.”

**ACKNOWLEDGMENTS**

Funding: This work was supported by the National Natural Science Fund Projects of China [grant number 81,470,671]; the National Key Research and Development Program of China [grant number 2016YFC1101103]; and the Foundation of Southwest Hospital [grant number [2016]308].

**REFERENCES**

1. Kaiser-Kupfer MI, Chan CC, Markello TC, Crawford MA, Caruso RC, Csaky KG, Guo J, Gahl WA. Clinical biochemical and pathologic correlations in Bietti's crystalline dystrophy. Am J Ophthalmol 1994; 118:569-82. [PMID: 7977570].
2. Jiao X, Munier FL, Iwata F, Hayakawa M, Kanai A, Lee J, Schorderet DF, Chen MS, Kaiser-Kupfer M, Hejtmancik JF. Genetic linkage of Bietti crystalline corneoretinal dystrophy to chromosome 4q35. Am J Hum Genet 2000; 67:1309-13. [PMID: 11001583].

3. Li A, Munier FL, Schorderet DF, Yao W, Iwata F, Hayakawa M, Kanai A, Shy Chen M, Alan Lewis R, Heckenlively J, Weleber RG, Traboulsi EL, Zhang Q, Xiao X, Kaiser-Kupfer M, Sergeev YV, Hejtmancik JF. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet 2004; 74:817-26. [PMID: 15042513].

4. Gekka T, Takeuchi T, Goto-Omoto S, Kitahara K. CYP4V2 mutations in two Japanese patients with Bietti’s crystalline dystrophy. Ophthal Res 2005; 37:262-9. [PMID: 16088246].

5. Lee KY, Koh AH, Aung T, Yong VH, Yeung K, Ang CL, Vithana EN. Characterization of Bietti crystalline dystrophy patients with CYP4V2 mutations. Invest Ophthalmol Vis Sci 2005; 46:3812-6. [PMID: 16186368].

6. Lin J, Nishiguchi KM, Nakamura M, Dryja TP, Berson EL, Miyake Y. Recessive mutations in the CYP4V2 gene in East Asian and Middle Eastern patients with Bietti crystalline corneoretinal dystrophy. J Med Genet 2005; 42:e38-[PMID: 15937078].

7. Shan M, Dong B, Zhao X, Wang J, Li G, Yang Y, Li Y. Novel mutations in the CYP4V2 gene associated with Bietti’s crystalline corneoretinal dystrophy. Mol Vis 2005; 11:738-43. [PMID: 16179904].

8. Wada Y, Tada A, Itabashi T, Kawamura M, Sato H, Tamai M. Screening for mutations in CYP4V2 gene in Japanese patients with Bietti’s crystalline corneoretinal dystrophy. Am J Ophthalmol. 2005; 139:894-9. [PMID: 15860296].

9. Jin ZB, Ito S, Saito Y, Inoue Y, Yanagi Y, Nao-I N. Clinical and molecular findings in three Japanese patients with crystalline retinopathy. Jpn J Ophthalmol 2006; 50:426-31. [PMID: 17013694].

10. Lai TY, Ng TK, Tam PO, Yam GH, Ngai JW, Chan WM, Liu DT, Lam DS, Pang CP. Genotype phenotype analysis of Bietti’s crystalline dystrophy in patients with CYP4V2 mutations. Invest Ophthalmol Vis Sci 2007; 48:5212-20. [PMID: 17962476].

11. Zenteno JC, Ayala-Ramirez R, Graue-Wiechers F. Novel CYP4V2 gene mutation in a Mexican patient with Bietti’s crystalline corneoretinal dystrophy. Curr Eye Res 2008; 33:313-8. [PMID: 18398705].

12. den Hollander AI, McGee TL, Ziviello C, Banfi S, Dryja TP, Gonzalez-Fernandez F, Ghosh D, Berson EL. A homozygous missense mutation in the IRBP gene (RBP3) associated with autosomal recessive retinitis pigmentosa. Invest Ophthalmol Vis Sci 2009; 50:1864-72. [PMID: 19074801].

13. Fong AM, Koh A, Lee K, Ang CL. Bietti’s crystalline dystrophy in Asians: clinical, angiographic and electrophysiological characteristics. Int Ophthalmol 2009; 29:459-70. [PMID: 18854949].

14. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009; 118:69-77. [PMID: 19030905].

15. Xiao X, Mai G, Li S, Guo X, Zhang Q. Identification of CYP4V2 mutation in 21 families and overview of mutation spectrum in Bietti crystalline corneoretinal dystrophy. Biochem Biophys Res Commun 2011; 409:181-6. [PMID: 21565171].

16. Yokoi Y, Sato K, Aoyagi H, Takahashi Y, Yamagami M, Nakanawa M. A Novel Compound Heterozygous Mutation in the CYP4V2 Gene in a Japanese Patient with Bietti’s Crystalline Dystrophy. Case Rep Ophthalmol 2011; 2:296-301. [PMID: 22087103].

17. Mamatha G, Umashankar V, Kasinathan N, Krishnan T, Sathyaabarrathi R, Karthikeyayini T, Amali J, Rao C, Madhavan J. Molecular screening of the CYP4V2 gene in Bietti crystalline dystrophy that is associated with choroidal neovascularization. Mol Vis 2011; 17:1970-7. [PMID: 21850171].

18. Meng XH, Guo H, Xu HW, Li QY, Jin X, Bai Y, Li SY, Yin ZQ. Identification of novel CYP4V2 gene mutations in 92 Chinese families with Bietti’s crystalline corneoretinal dystrophy. Mol Vis 2014; 20:1806-14. [PMID: 25593508].

19. Tian R, Wang SR, Wang J, Chen YX. Novel CYP4V2 mutations associated with Bietti crystalline corneoretinal dystrophy in Chinese patients. Int J Ophthalmol 2015; 8:465-9. [PMID: 26085992].

20. Liu DN, Liu Y, Meng XH, Yin ZQ. The characterization of functional disturbances in Chinese patients with Bietti’s crystalline dystrophy at different fundus stages. Graef Arch Clin Exp 2012; 250:191-200. [PMID: 21892605].

21. Zhang X, Xu K, Dong B, Peng X, Li Q, Jiang F, Xie Y, Tian L, Li Y. Comprehensive screening of CYP4V2 in a cohort of Chinese patients with Bietti crystalline dystrophy. Mol Vis 2018; 24:700-11. [PMID: 30429639].

22. Hirashima T, Miyata M, Ishiihara K, Hasegawa T, Sugahara M, Ogino K, Yoshikawa M, Hata M, Kuroda Y, Muraoka Y, Ooto S, Yoshimura N. Choroidal Vasculature in Bietti Crystalline Dystrophy With CYP4V2 Mutations and in Retinitis Pigmentosa With EYS Mutations. Invest Ophthalmol Vis Sci 2017; 58:3871-8. [PMID: 28763560].

23. Yin X, Yang L, Chen N, Cui H, Zhao L, Feng L, Li A, Zhang H, Ma Z, Li G. Identification of CYP4V2 mutation in 36 Chinese families with Bietti crystalline corneoretinal dystrophy. Exp Eye Res 2016; 146:154-62. [PMID: 26971461].

24. Park YJ, Hwang DJ, Seong MW, Park SS, Woo SJ. Bietti crystalline Retinopathy Confirmed by Mutation of CYP4V2 Gene in a Korean Patient. Korean J Ophthalmol 2016; 30:81-3. [PMID: 26865810].

25. Jiao X, Li A, Jin ZB, Wang X, Iannaccone A, Traboulsi EL, Gorin MB, Simonelli F, Heijtmancik JF. Identification and population history of CYP4V2 mutations in patients with Bietti crystalline corneoretinal dystrophy. Eur J Hum Genet 2017; 25:461-71. [PMID: 28051075].
26. Hu DN. Prevalence and mode of inheritance of major genetic eye diseases in China. J Med Genet 1987; 24:584-8. [PMID: 3500313].

27. Jin X, Qu LH, Hou BK, Xu HW, Meng XH, Pang CP, Yin ZQ. Novel compound heterozygous mutation in the CNGA1 gene underlie autosomal recessive retinitis pigmentosa in a Chinese family. Biosci Rep 2016; 36:e00289-[PMID: 26802146].

28. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25:1754-60. [PMID: 19451168].

29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38:e164-[PMID: 20601685].

30. Werck-Reichhart D, Feyereisen R. Cytochromes P450: a success story. Genome Biol 2000; 1:3003-[PMID: 11178272].

31. Degtyarenko KN, Archakov AI. Molecular evolution of P450 superfamily and P450-containing monoxygenase systems. FEBS Lett 1993; 332:1-8. [PMID: 8403421].

32. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, Degtyarenko KN, Archakov AI. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993; 12:1-51. [PMID: 7678494].

33. Graham-Lorence S, Amarneh B, White RE, Peterson JA, Simpson ER. A three-dimensional model of aromatase cytochrome P450. Protein Sci 1995; 4:1065-80. [PMID: 7549871].

34. Nebert DW, Gonzalez FJ. P450 genes: structure, evolution, and regulation. Annu Rev Biochem 1987; 56:945-93. [PMID: 3304150].

35. Guengerich FP. Reactions and significance of cytochrome P-450 enzymes. J Biol Chem 1991; 266:10019-22. [PMID: 2037557].

36. Lee J, Jiao X, Hejtmancik JF, Kaiser-Kupfer M, Gahl WA, Markello TC, Guo J, Chader GJ. The metabolism of fatty acids in human Bietti crystalline dystrophy. Invest Ophthalmol Vis Sci 2001; 42:1707-14. [PMID: 11431432].

37. Nakano M, Kelly EJ, Rettie AE. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. Drug Metab Dispos 2009; 37:2119-22. [PMID: 19661213].

38. Mackay DS, Halford S. Focus on molecules: cytochrome P450 family 4, subfamily V, polypeptide 2 (CYP4V2). Exp Eye Res 2012; 102:111-2. [PMID: 21745470].

39. Halford S, Liew G, Mackay DS, Sergouniotis PI, Holt R, Broadgate S, Volpi EV, Ocaña L, Robson AG, Holder GE, Moore AT, Michaelides M, Webster AR. Detailed phenotypic and genotypic characterization of bietti crystalline dystrophy. Ophthalmology 2014; 121:1174-84. [PMID: 24480711].

40. Rossi S, Testa F, Li A, Yaylacioglu F, Gesualdo C, Hejtmancik JF, Simonelli F. Clinical and genetic features in Italian Bietti crystalline dystrophy patients. Br J Ophthalmol 2013; 97:174-9. [PMID: 23221965].

41. Rossi S, Testa F, Li A, Iorio VD, Zhang J, Gesualdo C, Corte MD, Chan CC, Fielding Hejtmancik J, Simonelli F. An atypical form of Bietti crystalline dystrophy. Ophthalmic Genet 2011; 32:118-21. [PMID: 21385027].

42. Yin H, Jin C, Fang X, Miao Q, Zhao Y, Chen Z, Su Z, Ye P, Wang Y, Yin J. Molecular analysis and phenotypic study in 14 Chinese families with Bietti crystalline dystrophy. PLoS One 2014; 9:e94960-[PMID: 24739949].